The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression - PubMed (original) (raw)

The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression

Limo Chen et al. Oncoimmunology. 2015.

Abstract

Epithelial-mesenchymal transition and immunosuppression are crucial for cancer metastasis and treatment resistance. The mechanism by which these distinct processes are co-opted remains incompletely understood. Our recent work has exposed the "dirty affairs" of the 2 at the tumor site, thus calling for a combined therapy to break such a dangerous liaison.

Keywords: epithelial–mesenchymal transition; immunosuppression; miRNA; therapy resistance; tumor microenvironment.

PubMed Disclaimer

Figures

Figure 1.

Dangerous liaison between epithelial–mesenchymal transition and immunosuppression. The microRNA-200–ZEB1 axis instigates the interplay between cancer cells and immune cells in the tumor microenvironment.

Similar articles

• Tumor microenvironment and noncoding RNAs as co-drivers of epithelial-mesenchymal transition and cancer metastasis.
  Drak Alsibai K, Meseure D. Drak Alsibai K, et al. Dev Dyn. 2018 Mar;247(3):405-431. doi: 10.1002/dvdy.24548. Epub 2017 Sep 18. Dev Dyn. 2018. PMID: 28691356 Review.
• Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
  Begemann D, Anastos H, Kyprianou N. Begemann D, et al. Int J Urol. 2018 Apr;25(4):318-326. doi: 10.1111/iju.13505. Epub 2018 Jan 17. Int J Urol. 2018. PMID: 29345000 Review.
• Regulation of epithelial-mesenchymal transition by tumor-associated macrophages in cancer.
  Zhang J, Yao H, Song G, Liao X, Xian Y, Li W. Zhang J, et al. Am J Transl Res. 2015 Oct 15;7(10):1699-711. eCollection 2015. Am J Transl Res. 2015. PMID: 26692918 Free PMC article. Review.
• Tumor microenvironment participates in metastasis of pancreatic cancer.
  Ren B, Cui M, Yang G, Wang H, Feng M, You L, Zhao Y. Ren B, et al. Mol Cancer. 2018 Jul 30;17(1):108. doi: 10.1186/s12943-018-0858-1. Mol Cancer. 2018. PMID: 30060755 Free PMC article. Review.
• Oxystressed tumor microenvironment potentiates epithelial to mesenchymal transition and alters cellular bioenergetics towards cancer progression.
  Sridaran D, Ramamoorthi G, MahaboobKhan R, Kumpati P. Sridaran D, et al. Tumour Biol. 2016 Oct;37(10):13307-13322. doi: 10.1007/s13277-016-5224-6. Epub 2016 Jul 26. Tumour Biol. 2016. PMID: 27460079

Cited by

• Immune checkpoint inhibitor- and phosphatidylinositol-3-kinase inhibitor-related diabetes induced by antineoplastic drugs: two case reports and a literature review.
  Gao Y, Zhong M, Gan L, Xiang C, Li L, Yan Y. Gao Y, et al. Front Endocrinol (Lausanne). 2023 Sep 5;14:1236946. doi: 10.3389/fendo.2023.1236946. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37732122 Free PMC article.
• Tumor-mediated immunosuppression and cytokine spreading affects the relation between EMT and PD-L1 status.
  Lems CM, Burger GA, Beltman JB. Lems CM, et al. Front Immunol. 2023 Aug 10;14:1219669. doi: 10.3389/fimmu.2023.1219669. eCollection 2023. Front Immunol. 2023. PMID: 37638024 Free PMC article.
• Toripalimab-associated diabetes mellitus: a case report from the community of Southern China.
  Zhang W, Xu W. Zhang W, et al. Endocrinol Diabetes Metab Case Rep. 2023 Jun 21;2023(2):22-0387. doi: 10.1530/EDM-22-0387. Print 2023 Jun 1. Endocrinol Diabetes Metab Case Rep. 2023. PMID: 37341461 Free PMC article.
• Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer.
  Ding P, Wen L, Tong F, Zhang R, Huang Y, Dong X. Ding P, et al. Cancer Drug Resist. 2022 Feb 8;5(1):147-164. doi: 10.20517/cdr.2021.104. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35582541 Free PMC article. Review.
• The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects.
  Bravaccini S, Bronte G, Petracci E, Puccetti M, D'Arcangelo M, Ravaioli S, Tumedei MM, Maltoni R, Delmonte A, Cappuzzo F, Crinò L. Bravaccini S, et al. Front Cell Dev Biol. 2021 Nov 30;9:772216. doi: 10.3389/fcell.2021.772216. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34917615 Free PMC article.

References

1. 1. Radvanyi L. Immunotherapy exposes cancer stem cell resistance and a new synthetic lethality. Mol Ther 2013; 21:1472–4; PMID:; http://dx.doi.org/10.1038/mt.2013.160 - DOI - PMC - PubMed
2. 1. Shintani Y, Okimura A, Sato K, Nakagiri T, Kadota Y, Inoue M, Sawabata N, Minami M, Ikeda N, Kawahara K, et al.. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg 2011; 92:1794–804; discussion 1804; PMID:; http://dx.doi.org/10.1016/j.athoracsur.2011.07.032 - DOI - PubMed
3. 1. Li T, Zeng ZC, Wang L, Qiu SJ, Zhou JW, Zhi XT, Yu HH, Tang ZY. Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial-mesenchymal transition. Cancer Gene Ther 2011; 18:617–26; PMID:; http://dx.doi.org/10.1038/cgt.2011.29 - DOI - PubMed
4. 1. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al.. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014; 5:5241; PMID:; http://dx.doi.org/10.1038/ncomms6241. - DOI - PMC - PubMed
5. 1. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, et al.. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 2009; 23:2140–51; PMID:; http://dx.doi.org/10.1101/gad.1820209 - DOI - PMC - PubMed

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Taylor & Francis